Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis
Chunmei Li, Rui Han, Le Kang, Jianping Wang, Yonglin Gao, Yanshen Li, Jie He, Jingwei Tian, Chunmei Li, Rui Han, Le Kang, Jianping Wang, Yonglin Gao, Yanshen Li, Jie He, Jingwei Tian
Abstract
Pirfenidone (PFD), an anti-fibrotic small molecule drug, is used to treat fibrotic diseases, but its effects on myocardial infarction (MI)-induced cardiac fibrosis are unknown. The aim of this study was to determine the effects of PFD on MI-induced cardiac fibrosis and the possible underlying mechanisms in rats. After establishment of the model, animals were administered PFD by gavage for 4 weeks. During the development of MI-induced cardiac fibrosis, we found activation of a positive feedback loop between the angiotensin II type 1 receptor (AT1R)/phospho-p38 mitogen-activated protein kinase (p38 MAPK) pathway and renin-angiotensin system (RAS), which was accompanied by down-regulation of liver X receptor-α (LXR-α) expression. PFD attenuated body weight, heart weight, left ventricular weight, left ventricular systolic pressure, and ±dp/dtmax changes induced by MI, which were associated with a reduction in cardiac fibrosis, infarct size, and hydroxyproline concentration. Moreover, PFD inhibited the AT1R/p38 MAPK pathway, corrected the RAS imbalance [decreased angiotensin-converting enzyme (ACE), angiotensin II, and angiotensin II type 1 receptor expression, but increased ACE2 and angiotensin (1-7) activity and Mas expression] and strongly enhanced heart LXR-α expression. These results indicate that the cardioprotective effects of PFD may be due, in large part, to controlling the feedback loop of the AT1R/p38 MAPK/RAS axis by activation of LXR-α.
Figures
References
- Li N. et al.. Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP. J Mol Cell Cardiol 79, 303–314 (2015).
- Ainscough J. F. et al.. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 81, 592–600 (2009).
- Simões E., Silva A. C. & Teixeira M. M. ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. Pharmacol Res doi: 10.1016/j.phrs (2016).
- Matsuo T. et al.. Efficient long-term survival of cell grafts after myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells. Sci Rep 5, 16842 (2015).
- Sakurai T. et al.. Involvement of angiotensin II and reactive oxygen species in pancreatic fibrosis. Pancreatology: official journal of the International Association of Pancreatology 11 Suppl 2, 7–13 (2011).
- Zhao G. et al.. Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats. J Huazhong Univ Sci Technolog Med Sci 30, 48–54 (2010).
- Koka V. et al.. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 172, 1174–1183 (2008).
- Xiao L., Haack K. K. & Zucker I. H. Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen- 1 activated protein kinase and extracellular signal-regulated kinase 1/2 signaling. Am J Physiol Cell Physiol 304, C1073–C1079 (2013).
- Liu X., Gao J., Xia Q., Lu T. & Wang F. Increased mortality and aggravation of heart failure in liver X receptor-α knockout mice after myocardial infarction. Heart Vessels 31, 1370–9 (2016).
- Cannon M. V. et al.. Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol Med 7, 1229–43 (2015).
- Kuipers I. et al.. Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin–angiotensin–aldosterone system. Lab Invest 90, 630–636 (2010).
- Yan K. et al.. p38 mitogen-activated protein kinase and liver X receptor-α mediate the leptin effect on sterol regulatory element binding protein-1c expression in hepatic stellate cells. Mol Med 18, 10–8 (2012).
- Avila G., Osornio-Garduño D. S., Ríos-Pérez E. B. & Ramos-Mondragón R. Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus. Cell Calcium 56, 428–435 (2014).
- Yamagami K. et al.. Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts. Am J Physiol Heart Circ Physiol 309, H512–H522 (2015).
- Takakuta K. et al.. Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol 629, 118–24 (2010).
- Conte E. et al.. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 58, 13–9 (2014).
- Liu J. J. et al.. Improving vagal activity ameliorates cardiac fibrosis induced by angiotensin II: in vivo and in vitro. Sci Rep 5, 17108 (2015).
- Miyamoto A. et al.. Marked improvement with Pirfenidone in a patient with idiopathic pulmonary fibrosis. Intern Med 55, 657–661 (2016).
- Patel V. B. et al.. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res 110, 1322–1335 (2012).
- Patel B. M. & Mehta A. A. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. Eur J Pharmacol 697, 1–12 (2012).
- Liu Q. et al.. Renal denervation findings on cardiac and renal fibrosis in rats with isoproterenol induced cardiomyopathy. Sci Rep 5, 18582 (2015).
- Ferrario C. M. et al.. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605–2610 (2005).
- Der. Sarkissian S. et al.. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51, 712–718 (2008).
- Al-Majed A. R., Assiri E., Khalil N. Y. & Abdel-Aziz H. A. Losartan: comprehensive profile. Profiles Drug Subst Excip Relat Methodol 40, 159–94 (2015).
- Wang X. et al.. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol 97, 180–190 (2016).
- Beyer C. et al.. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Ann Rheum Dis 74, 1317–24 (2015).
- Ahn S. B., Jang K., Jun D. W., Lee B. H. & Shin K. J. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 59, 2975–82 (2014).
- Leik C. E. et al.. GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br J Pharmacol 151, 450–456 (2007).
- Cannon M. V. et al.. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. Eur J Heart Fail 17, 273–282 (2015).
- Passos-Silva D. G., Verano-Braga T. & Santos R. A. Angiotensin-(1-7): beyond the cardio-renal actions.Clin Sci (Lond) 124, 443–456 (2013).
- Kang X. H. Effect of Ang II and Ang (1-7) on PPARγand LXR-α expression in THP-1 macrophage, and the interaction between them. Shanxi Medical University. Chinese Journal of Arteriosclerosis (2011).
- Wang Y. et al.. Activation of liver X receptor improves viability of adipose-derived mesenchymal stem cells to attenuate myocardial ischemia injury through TLR4/NF-κB and Keap-1/Nrf-2 signaling pathways. Antioxid Redox Signal 21, 2543–2557 (2014).
- Liu L. N., He B., Wu Y. X., Liang S. & Shen X. Y. Effects of rosuvastatin plus losartan on liver X receptor mRNA expression in human monocyte-macrophages induced by oxidized low-density lipoprotein. Chinese Remedies & Clinics 14, 721–723 (2014).
- Li C., Gao Y., Tian J., Xing Y., Zhu H. & Shen J. Long-term oral Asperosaponin VI attenuates cardiac dysfunction, myocardial fibrosis in a rat model of chronic myocardial infarction. Food Chem Toxicol 50, 1432–1438 (2012).
- Takagawa J. et al.. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. J Appl Physiol 102, 2104–2111 (2007).
Source: PubMed